Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Professor Yang Shi from the Ludwig Institute for Cancer Research at NDM has been elected as a member of the National Academy of Sciences in the United States.

The National Academy of Sciences (NAS) is a private, non-profit organisation of the leading researchers in the US and beyond. The NAS recognises and promotes outstanding science through election to membership; publication in its journal - Proceedings of the National Academy of Sciences; and its awards, programs, and special activities. Through the National Academies of Sciences, Engineering, and Medicine, the NAS provides objective, science-based advice on critical issues.

Prof Yang Shi, Professor of Epigenetics at the Ludwig Institute for Cancer Research, has previously worked at Harvard Medical School. His interests lie in identifying key epigenetic regulators of cancer, determining their mechanism of action and providing the conceptual basis for translating these basic findings to the clinic. Yang and his group discovered the first histone methyl eraser, LSD1, in 2004 and have demonstrated that histone methylation is dynamically regulated.

At NDM, Yang’s team focuses primarily on two cancers, acute myeloid leukaemia and diffuse intrinsic pontine glioma, where epigenetics have been shown to play a crucial role in the maintenance of a poorly differentiated state.

Similar stories

Rift Valley fever vaccine to enter Phase II clinical trials in Kenya

A promising human vaccine candidate against the potentially deadly Rift Valley fever, a mosquito-borne disease affecting countries across Africa, is set to begin Phase II trials in Kenya. This is the most advanced stage of testing a human Rift Valley fever vaccine has reached in an outbreak-prone area to date. A team of scientists at the Nuffield Department of Medicine and the KEMRI-Wellcome Trust Research Programme will lead the $3.7m trial, funded by the Coalition for Epidemic Preparedness Innovations (CEPI).